Literature DB >> 30187322

Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms.

Katherine E Poruk1, James Griffin1, Martin A Makary1, Jin He1, John L Cameron1, Matthew J Weiss1, Laura D Wood2, Michael Goggins3,4, Christopher L Wolfgang5.   

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions to the development of pancreatic adenocarcinoma. We determined if non-O blood groups are more common in patients with IPMN and if blood group is a risk factor for progression to invasive pancreatic cancer among patients with IPMN.
METHODS: The medical records were reviewed of all patients undergoing resection of an IPMN at Johns Hopkins Hospital from June 1997 to August 2016. Potential risk factors of high-grade dysplasia and associated adenocarcinoma were identified through a multivariate logistic regression model.
RESULTS: Seven hundred and seventy-seven patients underwent surgical resection of an IPMN in which preoperative blood type was known. Sixty-two percent of IPMN patients had non-O blood groups (vs. 57% in two large US reference cohorts, P = 0.002). The association between non-O blood group was significant for patients with IPMN with low- or intermediate-grade dysplasia (P < 0.001), not for those with high-grade dysplasia (P = 0.68). Low- and intermediate-grade IPMNs were more likely to have non-type O blood compared to those with high-grade IPMN and/or associated invasive adenocarcinoma (P = 0.045). Blood type O was an independent predictor of having high-grade dysplasia without associated adenocarcinoma (P = 0.02), but not having associated invasive cancer (P = 0.72). The main risk factor for progression to invasive cancer after surgical resection was IPMN with high-grade dysplasia (P = 0.002).
CONCLUSION: IPMN patients are more likely to have non-O blood groups than controls, but type O blood group carriers had higher odds of having high-grade dysplasia in their IPMN. These results indicate blood group status may have different effects on the risk and progression of IPMNs.

Entities:  

Keywords:  ABO; Blood type; High-grade dysplasia; IPMN; Intraductal papillary mucinous neoplasm; Pancreatic cancer; Pancreatic ductal adenocarcinoma

Mesh:

Substances:

Year:  2018        PMID: 30187322      PMCID: PMC6399082          DOI: 10.1007/s11605-018-3795-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Suresh T Chari; Dhiraj Yadav; Thomas C Smyrk; Eugene P DiMagno; Laurence J Miller; Massimo Raimondo; Jonathan E Clain; Ian A Norton; Randall K Pearson; Bret T Petersen; Maurits J Wiersema; Michael B Farnell; Michael G Sarr
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

3.  Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.

Authors:  Roberto Salvia; Carlos Fernández-del Castillo; Claudio Bassi; Sarah P Thayer; Massimo Falconi; William Mantovani; Paolo Pederzoli; Andrew L Warshaw
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

4.  Long-term follow up results of intraductal papillary mucinous tumors of pancreas.

Authors:  Sun-Young Lee; Kyu Taek Lee; Jong Kyun Lee; Yong Hwan Jeon; Dongil Choi; Jae Hoon Lim; Jin Seok Heo; Seong Ho Choi; Kee-Taek Jang; Seung Woon Paik; Jong Chul Rhee
Journal:  J Gastroenterol Hepatol       Date:  2005-09       Impact factor: 4.029

5.  Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.

Authors:  Satoshi Nara; Hiroaki Onaya; Nobuyoshi Hiraoka; Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Minoru Esaki; Tomoo Kosuge
Journal:  Pancreas       Date:  2009-01       Impact factor: 3.327

6.  ABO blood group and the risk of pancreatic cancer.

Authors:  Brian M Wolpin; Andrew T Chan; Patricia Hartge; Stephen J Chanock; Peter Kraft; David J Hunter; Edward L Giovannucci; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

7.  Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection.

Authors:  Kazuyuki Nagai; Ryuichiro Doi; Atsushi Kida; Kazuhiro Kami; Yoshiya Kawaguchi; Tatsuo Ito; Takaki Sakurai; Shinji Uemoto
Journal:  World J Surg       Date:  2008-02       Impact factor: 3.352

8.  Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules.

Authors:  Yoshihiko Sadakari; Jun Ienaga; Kiichiro Kobayashi; Yoshihiro Miyasaka; Shunichi Takahata; Masafumi Nakamura; Kazuhiro Mizumoto; Masao Tanaka
Journal:  Pancreas       Date:  2010-03       Impact factor: 3.327

9.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer.

Authors:  Laufey Amundadottir; Peter Kraft; Rachael Z Stolzenberg-Solomon; Charles S Fuchs; Gloria M Petersen; Alan A Arslan; H Bas Bueno-de-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Wei Zheng; Demetrius Albanes; William Bamlet; Christine D Berg; Franco Berrino; Sheila Bingham; Julie E Buring; Paige M Bracci; Federico Canzian; Françoise Clavel-Chapelon; Sandra Clipp; Michelle Cotterchio; Mariza de Andrade; Eric J Duell; John W Fox; Steven Gallinger; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Carlos A González; Göran Hallmans; Susan E Hankinson; Manal Hassan; Elizabeth A Holly; David J Hunter; Amy Hutchinson; Rebecca Jackson; Kevin B Jacobs; Mazda Jenab; Rudolf Kaaks; Alison P Klein; Charles Kooperberg; Robert C Kurtz; Donghui Li; Shannon M Lynch; Margaret Mandelson; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Sara H Olson; Kim Overvad; Alpa V Patel; Petra H M Peeters; Aleksandar Rajkovic; Elio Riboli; Harvey A Risch; Xiao-Ou Shu; Gilles Thomas; Geoffrey S Tobias; Dimitrios Trichopoulos; Stephen K Van Den Eeden; Jarmo Virtamo; Jean Wactawski-Wende; Brian M Wolpin; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Stephen J Chanock; Patricia Hartge; Robert N Hoover
Journal:  Nat Genet       Date:  2009-08-02       Impact factor: 38.330

10.  Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center.

Authors:  Song C Kim; Kwan T Park; Young J Lee; Sang S Lee; Dong W Seo; Seong K Lee; Myung H Kim; Se J Jang; Jae H Byun; Duck J Han
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-04-06
View more
  2 in total

1.  Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms.

Authors:  Gabriele Capurso; Stefano Crippa; Giuseppe Vanella; Mariaemilia Traini; Giulia Zerboni; Piera Zaccari; Giulio Belfiori; Manuel Gentiluomo; Tommaso Pessarelli; Maria Chiara Petrone; Daniele Campa; Massimo Falconi; Paolo Giorgio Arcidiacono
Journal:  JAMA Netw Open       Date:  2020-11-02

2.  Identification of key lncRNAs in the tumorigenesis of intraductal pancreatic mucinous neoplasm by coexpression network analysis.

Authors:  Jun Ding; Yi Li; Yong Zhang; Bin Fan; Qinghe Li; Jian Zhang; Jiayao Zhang
Journal:  Cancer Med       Date:  2020-04-02       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.